Navigation Links
Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
Date:4/24/2013

SUNNYVALE, Calif., April 24, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will report financial results and recent developments for its three months ended March 31, 2013 after the NASDAQ Market closes on Wednesday, May 1, 2013.  The Company will conduct a conference call and audio webcast at 4:30 p.m ET on the same day. As previously announced, the Company changed its fiscal year end from June 30 to December 31, effective December 31, 2012. As a result, the three months ended March 31, 2013 represents the Company's fiscal 2013 first quarter.

Conference call and webcast details:

Date: May 1, 2013
Time: 4:30 PM ET
Listen via Internet: http://ir.pharmacyclics.com/events.cfm
Toll-free: (877)-407-0778
International: (201)-689-8565

Replay Number (Toll Free): (877)-660-6853
Replay Number (International): (201)-612-7415
Conference ID #: 413317

A webcast replay will be available on the Pharmacyclics website for 30 days.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical de
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
2. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
3. Pharmacyclics, Inc. Prices Public Offering of Common Stock
4. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
5. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
6. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
7. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
8. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
9. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
10. Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
11. Anterios, Inc., Announces Corporate Financing To Further Clinical Development Of Its Topical Botulinum Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014  Edwards Lifesciences Corporation (NYSE: ... of heart valves and hemodynamic monitoring, announced that Edwards, ... served as an expert panelist at the invitation of ... Health to discuss medical device innovation at its hearing, ... Evidence Development and Communication." "Edwards has five ...
(Date:7/22/2014)... 22, 2014  Jazz Pharmaceuticals plc (Nasdaq: ... 2014 second quarter financial results on Tuesday, August 5, ... management will host a live audio webcast immediately following ... provide a business and financial update and discuss second ... access the live audio webcast via the Investors & ...
(Date:7/22/2014)... Research and Markets has announced the addition ... Reagent, by Application - Global Forecast to 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Biopharmaceuticals are pharmaceutical products isolated ... most important and widely used techniques for biopharmaceutical production. ... cell culture market in 2013. Growth in the biopharmaceutical ...
Breaking Medicine Technology:Edwards' CEO Invited To Address Congress On Opportunities To Revitalize Medical Device Innovation 2Jazz Pharmaceuticals to Report 2014 Second Quarter Financial Results on August 5, 2014 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 3
... ) announced today that its Board of Directors approved a regular cash dividend payment of $0.0425 per share. , ... , , ... ... The dividend is payable on May 7, 2010 to shareholders of record as of April 6, 2010 . , ...
... ... , ... ... SILVER SPRING, Md. , March 22 FDA is recommending that healthcare practitioners temporarily suspend use of ...
Cached Medicine Technology:Components of Extraneous Virus Detected in Rotarix Vaccine; No Known Safety Risk 2Components of Extraneous Virus Detected in Rotarix Vaccine; No Known Safety Risk 3Components of Extraneous Virus Detected in Rotarix Vaccine; No Known Safety Risk 4
(Date:7/22/2014)... Steven Reinberg HealthDay Reporter ... are obese during pregnancy may be more likely to have ... "We found that, compared with children born from mothers ... during pregnancy had up to 20 to 30 percent higher ... assistant professor of pediatrics at Children,s Hospital of Pittsburgh. ...
(Date:7/22/2014)... (WASHINGTON, July 22, 2014) The American Society of ... Vanderbilt University School of Medicine, and Robert P. Hebbel, ... the 2014 Ernest Beutler Lecture and Prize for their ... disease. , The Ernest Beutler Lecture, named for the ... and physician-scientist for more than 50 years, is a ...
(Date:7/22/2014)... a member of the Clean Plate Club you eat ... not alone! A new Cornell University study shows that ... puts on his or her plate. "If you ... says Brian Wansink Ph.D., author of the forthcoming book, Slim ... Food and Brand Lab. , Wansink and co-author Katherine Abowd ...
(Date:7/22/2014)... Dr. Ross Feldman says women are often in the dark. ... disease, however, data has shown that post-menopausal women are just ... less likely to be adequately diagnosed and treated. New research ... British Journal of Clinical Pharmacology brings to light a ... identify which women are more prone to heart disease. , ...
(Date:7/22/2014)... D.C. (PRWEB) July 22, 2014 ... “Ensuring Seniors Access to Local Pharmacies Act of ... Medicare Part D would undermine the availability of ... spending by $21 billion over the next 10 ... Company released by the Pharmaceutical Care Management Association ...
Breaking Medicine News(10 mins):Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 2Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:Gene variant identified as a heart disease risk factor for women 2Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2
... LONDON, November 11 Extensive research conducted by the,Imperial ... on the Simbionix PROcedure Rehearsal Studio(TM), was awarded a,Magna ... in Lisbon, Portugal. , The ... world,s first patient specific system to enable clinicians to ...
... ... the home or office using methods and products that are government-approved, but that won,t harm ... ... present The Natural Flu Protection Kit, the first product to emerge from the company’s partnership ...
... ... , ... November 11, 2009 -- HEALTHeCAREERS , North America’s premier healthcare Network, is advertising ... the medical industry continues to be one of the few bright spots in the ...
... ... and the Beyond the Box team can assist seniors and their loved ones with the ... ... relocation and design firm, Beyond the Box , is pleased to announce its new ...
... The following statement can be attributed to Steven ... the American Chemistry Council (ACC) regarding the study published ... the Risk of Self-Reported Male Sexual Dysfunction," by D. ... study of occupational exposure to bisphenol A (BPA) among ...
... School of Public Health researchers will present Nov. 11 ... Health Association,s annual meeting in Philadelphia, including a study ... large-scale worksite wellness program. Additional public health ... Does faith affect how Southern African-American women use ...
Cached Medicine News:Health News:Research on Simbionix PROcedure Rehearsal Software Awarded Magna Cum Laude Prize at CIRSE 2009 2Health News:Research on Simbionix PROcedure Rehearsal Software Awarded Magna Cum Laude Prize at CIRSE 2009 3Health News:Green Living Expert Annie B. Bond's Natural Flu Protection Kit 2Health News:Green Living Expert Annie B. Bond's Natural Flu Protection Kit 3Health News:Healthcare Web Site Boasts Thousands of Jobs in a Down Economy 2Health News:Relocation Specialists Beyond the Box Team With Nurse to Help Facilitate Senior Moves 2Health News:Relocation Specialists Beyond the Box Team With Nurse to Help Facilitate Senior Moves 3Health News:Findings from New Study on Occupational Exposure to BPA of Limited Relevance to Consumers 2Health News:Worksite wellness programs may reduce employee absenteeism 2
Micro suture forceps....
Mini blades....
... M520 OH3 is a smart ... performance available on the market ... stand. The Leica M520 OH3 ... greatest range of movement and ...
Operating microscope with motorized zoom and variable focus up to 405 mm....
Medicine Products: